Anorexia Nervosa Is Characterized by Increased Adiponectin Plasma Levels and Reduced Nonoxidative Glucose Metabolism

Pannacciulli, Nicola; Vettor, Roberto; Milan, Gabriella; Granzotto, Marnie; Cignetti, Alessandro; Federspil, Giovanni; Giacomo, Piero De; Giorgino, R; Pergola, Giovanni De

doi:10.1210/jc.2002-021215

Cited by 152 publications

(92 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are not in agreement with the study of Housova et al (2005), which did not observe any difference between R-AN and BP-AN forms. Other studies showed an increase in serum adiponectin levels in AN but did not deal with AN subtypes Pannacciulli et al, 2003). However, it is noteworthy that Monteleone et al (2003) documented a significant increase of circulating adiponectin levels in patients with bulimia nervosa and a correlation of this increased adipocytokine secretion with the frequency of binge/purge episodes.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Specific adipocytokines profiles in patients with hyperactive and/or binge/purge form of anorexia nervosa

et al. 2010

View full text Add to dashboard Cite

Objective: The aim of our study was to determine whether eating behaviors and/or physical activity level may explain contradicting results in adipocytokines levels in anorexia nervosa (AN). Subjects/Methods: Fasting levels of circulating adipocytokines (adiponectin, resistin and leptin), insulin, glucose, C-reactive protein, cytokines (tumor necrosis factor-a and interleukin (IL)-1b), body composition and resting energy expenditure were measured in 24 women AN patients and 14 women controls. These parameters were compared according to AN subtypes: 15 patients with restrictive (R-AN) form versus 9 patients with binge/purge (BP-AN) form; 15 patients with hyperactive (H-AN) form versus 9 patients with nonhyperactive (NH-AN) form. Results: BP-AN patients had significantly higher serum adiponectin levels compared with R-AN patients (Po0.05), and H-AN patients had higher serum leptin and lower serum resistin levels compared with NH-AN patients (Po0.05 for both). Conclusions: Our study shows specific adipocytokines profiles depending on the subtype of AN: restrictive versus binge/purge and hyperactive versus Nonhyperactive forms. We suggest that these biological signatures could interfere with the outcome of the disease.

show abstract

Section: Discussionmentioning

confidence: 93%

“…Serum adiponectin has been found to be either increased Pannacciulli et al, 2003), normal (Iwahashi et al, 2003) or decreased (Tagami et al, 2004) in AN patients. Likewise, serum plasma resistin levels have been found to be either decreased (Dostalova et al, 2006) or normal (Dolezalova et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Specific adipocytokines profiles in patients with hyperactive and/or binge/purge form of anorexia nervosa

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[7][8][9][10][11] Adiponectin serum levels inversely correlate to body weight. Thus, low adiponectin levels are found in obesity, 10,11 and high levels are found in anorexia nervosa 12 and during weight loss. 13 Low adiponectin levels are also associated with insulin resistance and development of diabetes mellitus, 14 and administration of adiponectin is associated with increased insulin sensitivity and fatty acid catabolism.…”

mentioning

confidence: 95%

Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients

Wolf

Sadetzki

Kanety

et al. 2006

Cancer

163

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of the interleukin‐1 inhibitor rilonacept (interleukin‐1 Trap) for gout flare prevention during initiation of uric acid–lowering therapy (ULT). Methods In total, 241 adult patients with gout, ≥2 gout flares within the past year, and a serum urate level ≥7.5 mg/dl were initiated on allopurinol 300 mg daily and randomly allocated in a 1:1:1 ratio to receive 16 once‐weekly subcutaneous injections of placebo, rilonacept 80 mg, or rilonacept 160 mg, with a double (loading) dose on day 1. Allopurinol was titrated to achieve a serum urate level of <6.0 mg/dl. The study was powered for the primary efficacy end point, the number of gout flares per patient through week 16. Results More patients in the rilonacept groups (80.0% in the rilonacept 80 mg group, 86.4% in the rilonacept 160 mg group) completed the study than in the placebo group (72.5%; P < 0.05 for the rilonacept 160 mg group versus the placebo group). Over 16 weeks, the mean number of gout flares per patient was significantly reduced by rilonacept treatment (placebo: 1.06, rilonacept 80 mg: 0.29 [P < 0.001], rilonacept 160 mg: 0.21 [P < 0.001]). Significantly lower proportions of patients reported ≥1 gout flares with rilonacept 80 mg (18.8%) and rilonacept 160 mg (16.3%) relative to placebo (46.8%; P < 0.001 for both). Except for injection site reactions (1.3% in the placebo group versus 8.8% in the rilonacept 80 mg group [P = 0.0635, post hoc analysis] and 19.8% in the rilonacept 160 mg group [P = 0.0001, post hoc analysis]), the incidence of adverse events was generally balanced among the treatment groups. Conclusion Rilonacept markedly reduced the occurrence of gout flares associated with the initiation of ULT. The efficacy and safety profile suggests that rilonacept may have the potential to improve long‐term disease control for some patients by improving adherence to ULT by reducing flares during the first months after ULT initiation.

show abstract

“…Disturbances in hormonal regulation or nutrition may increase the risk for NAFLD. For example, insulin resistance, occasionally seen in AN [9][10], increases peripheral fatty acid mobilization and decreases hepatic oxidation of fatty acids. Although the relationship between insulin resistance and NAFLD has been welldescribed in obese and normal-weight individuals [11], it has not been explored in AN.…”

mentioning

confidence: 99%

Prevalence and Predictors of Abnormal Liver Enzymes in Young Women with Anorexia Nervosa

Fong

DiVasta²,

DiFabio³

et al. 2008

The Journal of Pediatrics

View full text Add to dashboard Cite

Objective-To determine the prevalence and predictors of abnormal liver enzyme levels in ambulatory young women with anorexia nervosa (AN).Study design-In this cross-sectional study of 53 females with AN, serum concentrations of liver enzymes and hormones were measured. Anthropometric, dietary, and body composition information was collected. Correlational analyses were performed between liver enzyme concentrations and these variables.Results-Elevated alanine aminotransferase (ALT) and gamma-glutamyltranspeptidase (GGT) levels were found in 14 subjects (26%) and 5 subjects (9%), respectively. ALT and GGT were inversely correlated with body mass index (r = −0.27 to −0.30, p ≤ 0.049) and percentage body fat (r = −0.36 to −0.47, p ≤ 0.007), but showed no relationship with lean body mass. Subjects with percentage body fat < 18% had higher ALT levels than those above this threshold (median 26.5 vs. 18.0 U/L, p = 0.01). Liver enzyme concentrations did not correlate with dietary variables, except for GGT and percentage of calories from protein (r = 0.28, p = 0.04).Conclusions-Serum ALT and GGT concentrations are inversely related to adiposity in young women with AN. Future studies are needed to determine if these liver enzyme elevation signify unrecognized, clinically relevant liver disease.Keywords eating disorders; adolescents; liver; malnutrition; alanine aminotransferase; gammaglutamyltranspeptidase Corresponding author: Catherine M. Gordon, MD, MSc, Divisions of Adolescent Medicine and Endocrinology, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02215, Tel: 617-355-8492, Fax: 617-730-0195, Email: catherine.gordon@childrens.harvard.edu For reprints, please contact the corresponding author, Catherine M. Gordon, MD, MSc. Edited by WFB Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. In this study, we sought to determine the prevalence and predictors of abnormal liver enzyme levels in ambulatory young women with AN. We hypothesized that individuals with more severe disease, as reflected by lower body mass index (BMI) and body fat, would be more likely to exhibit elevated ALT and gamma-glutamyltranspeptidase (GGT) levels. We also hypothesized that insulin resistance would be a predictor of abnormal ALT and GGT concentrations. We predicted that there would be a significant association between macronutrient caloric distribution and liver enzyme concentrations. Methods DesignThis study was a cross-sectional evaluation of data obtained from the baseline visit of a clinical bone density trial. SubjectsAdolescents and young women with AN were recruited from the Chil...

show abstract

Anorexia Nervosa Is Characterized by Increased Adiponectin Plasma Levels and Reduced Nonoxidative Glucose Metabolism

Cited by 152 publications

References 38 publications

Specific adipocytokines profiles in patients with hyperactive and/or binge/purge form of anorexia nervosa

Specific adipocytokines profiles in patients with hyperactive and/or binge/purge form of anorexia nervosa

Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients

Prevalence and Predictors of Abnormal Liver Enzymes in Young Women with Anorexia Nervosa

Contact Info

Product

Resources

About